News

Astellas Pharma Canada, Inc. Recognized Again as a Best Workplace™ in Ontario MARKHAM, ON, November 17, 2022 – Astellas Pharma Canada, Inc. is proud to announce that our organization has been named on the 2022 list of Best Workplaces™ in Ontario by Great Place to Work® for the third year in a row. This recognition comes in addition to being listed for the seventh consecutive year as a Best...

Astellas Pharma Canada, Inc. Named a Best Workplace™ in Healthcare MARKHAM, ON, September 13, 2022 – Astellas Pharma Canada, Inc. is pleased to announce it has been named to the 2022 list of Best Workplaces™ in Healthcare by Great Place to Work® for the fourth year in a row in Canada. The recognition is a reflection of Astellas Pharma Canada employees’ commitment to the company’s vision to be on...

XTANDI is the only treatment approved for three clinical disease states across four indications, and the improved access for mCSPC patients will support earlier treatment MARKHAM, ON, June 23, 2022 /CNW/ - Astellas Pharma Canada, Inc., announces that XTANDI® (enzalutamide), an oral once-daily therapy,1 is now reimbursed across most of Canada for the treatment of patients with metastatic castration...

MARKHAM, ON, April 29, 2022 – Astellas Pharma Canada, Inc., a leader in innovative medicines headquartered in Markham, Ontario recognizes the Ontario government for the commitment of $15-million over three years for the new Life Sciences Innovation Program outlined in the Spring Budget. "Our vision at Astellas is to stand on the forefront of healthcare change, turning innovative science into value...

Astellas ranked 47th on the Best Workplaces™ in Canada list MARKHAM, ON, April 27, 2022 – Astellas Pharma Canada, Inc. has been named again on the list of Best Workplaces™ in Canada by the Great Place to Work® Institute, marking the seventh year in a row to receive this recognition. The Institute honours employers across the country who create and foster exemplary workplaces. This year Astellas...